These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25232025)

  • 41. Retinal arteriolar dilation to flicker light is reduced on short-term retesting.
    Noonan JE; Nguyen TT; Man RE; Best WJ; Wang JJ; Lamoureux EL
    Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7764-8. PubMed ID: 24168997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glaucomatous visual field progression with frequency-doubling technology and standard automated perimetry in a longitudinal prospective study.
    Haymes SA; Hutchison DM; McCormick TA; Varma DK; Nicolela MT; LeBlanc RP; Chauhan BC
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):547-54. PubMed ID: 15671281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Which method of flicker perimetry is most effective for detection of glaucomatous visual field loss?
    Yoshiyama KK; Johnson CA
    Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2270-7. PubMed ID: 9344350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between Humphrey 30-2 SITA Standard Test, Matrix 30-2 threshold test, and Heidelberg retina tomograph in ocular hypertensive and glaucoma patients.
    Bozkurt B; Yilmaz PT; Irkec M
    J Glaucoma; 2008; 17(3):203-10. PubMed ID: 18414106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regional variability in visual field sensitivity during hypercapnia.
    Hilton EJ; Hosking SL; Cubbidge RP; Morgan AJ
    Am J Ophthalmol; 2003 Aug; 136(2):272-6. PubMed ID: 12888049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An investigation of the visual disturbances experienced by patients on clomiphene citrate.
    Racette L; Casson PR; Claman P; Zackon DH; Casson EJ
    Fertil Steril; 2010 Mar; 93(4):1169-72. PubMed ID: 19135656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of frequency-doubling technology for perimetrically normal eyes of open-angle glaucoma patients with unilateral field loss.
    Fan X; Wu LL; Ma ZZ; Xiao GG; Liu F
    Ophthalmology; 2010 Aug; 117(8):1530-7, 1537.e1-2. PubMed ID: 20466428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequency doubling technology for earlier detection of functional damage in standard automated perimetry-normal hemifield in glaucoma with low-to-normal pressure.
    Nakagawa S; Murata H; Saito H; Nakahara H; Mataki N; Tomidokoro A; Iwase A; Araie M
    J Glaucoma; 2012 Jan; 21(1):22-6. PubMed ID: 21543995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Properties of the regained visual field after visual detection training of hemianopsia patients.
    Bergsma DP; Van der Wildt GJ
    Restor Neurol Neurosci; 2008; 26(4-5):365-75. PubMed ID: 18997312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diffuse and localized glaucomatous visual field changes in light sense, flicker and visual acuity perimetry. Evidence of pressure damage].
    Lachenmayr BJ; Drance SM; Chauhan BC; House PH; Lalani S
    Fortschr Ophthalmol; 1991; 88(5):530-7. PubMed ID: 1757044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance of frequency-doubling technology perimetry in a population-based prevalence survey of glaucoma: the Tajimi study.
    Iwase A; Tomidokoro A; Araie M; Shirato S; Shimizu H; Kitazawa Y;
    Ophthalmology; 2007 Jan; 114(1):27-32. PubMed ID: 17070580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between retinal nerve fiber layer and visual field function in human immunodeficiency virus-infected patients without retinitis.
    Arantes TE; Garcia CR; Tavares IM; Mello PA; Muccioli C
    Retina; 2012 Jan; 32(1):152-9. PubMed ID: 21716164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topographic relationship between frequency-doubling technology threshold values.
    Fuertes-Lazaro I; Sanchez-Cano A; Ferreras A; Larrosa JM; Garcia-Martin E; Pablo LE
    Acta Ophthalmol; 2012 Mar; 90(2):e144-50. PubMed ID: 22103468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rates of change in the visual field and optic disc in patients with distinct patterns of glaucomatous optic disc damage.
    Reis AS; Artes PH; Belliveau AC; Leblanc RP; Shuba LM; Chauhan BC; Nicolela MT
    Ophthalmology; 2012 Feb; 119(2):294-303. PubMed ID: 22133797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vision restoration training for glaucoma: a randomized clinical trial.
    Sabel BA; Gudlin J
    JAMA Ophthalmol; 2014 Apr; 132(4):381-9. PubMed ID: 24504128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency doubling technology perimetry in open-angle glaucoma eyes with hemifield visual field damage: comparison of high-tension and normal-tension groups.
    Murata H; Tomidokoro A; Matsuo H; Tomita G; Araie M
    J Glaucoma; 2007 Jan; 16(1):9-13. PubMed ID: 17224743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-function correlations in glaucoma using matrix and standard automated perimetry versus time-domain and spectral-domain OCT devices.
    Pinto LM; Costa EF; Melo LA; Gross PB; Sato ET; Almeida AP; Maia A; Paranhos A
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(5):3074-80. PubMed ID: 24722699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of the normative database for the Humphrey matrix perimeter.
    Anderson AJ; Johnson CA; Fingeret M; Keltner JL; Spry PG; Wall M; Werner JS
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1540-8. PubMed ID: 15790927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meridional differences in temporal response characteristics.
    Styles T; Flanagan JG
    Ophthalmic Physiol Opt; 1989 Oct; 9(4):405-10. PubMed ID: 2631007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Critical flicker fusion test of potential vision.
    Shankar H; Pesudovs K
    J Cataract Refract Surg; 2007 Feb; 33(2):232-9. PubMed ID: 17276263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.